Is there a generic version of adagrasib?

Adagrasib is a new type of anti-cancer drug that is a small molecule targeted therapy drug and is used to treat some thymic cancers and non-small cell lung cancer. Its development represents a major breakthrough in cancer treatment, providing patients with new treatment options.

Since adagrasib is not yet available in the country, patients are currently unable to purchase it directly domestically and must resort to overseas channels. However, the original drug of adagrasib abroad, mainly from the United States, is extremely expensive, reaching more than 180,000 yuan, which is undoubtedly a heavy burden for ordinary families.

But what is gratifying is that foreign generic drugs have recently come out. Among them, the generic drug of adagrasibu produced by Lucius in Laos has attracted much attention. Its price is relatively affordable, only about four to five thousand yuan per box. More importantly, after comparison, it was found that the ingredients of this generic drug are basically the same as the original drug, providing patients with a more economical and affordable choice.

Adagarasib works by inhibiting a mutant protein calledKRAS G12C. This mutation is found in many tumor types, including some thymic cancers and non-small cell lung cancer. KRAS G12CMutation promotes abnormal proliferation and growth of cancer cells, and adagrasib can precisely target this abnormality and inhibit its activity, thereby inhibiting the proliferation of cancer cells.

Clinical trials have shown that adagrasib shows good efficacy in some patients with thymic cancer and non-small cell lung cancer. Patients can usually observe tumor shrinkage and symptom relief after taking this drug, which helps prolong patients' survival and improve their quality of life.

Adagrasiib is better tolerated and has fewer side effects than traditional chemotherapy drugs. This allows patients to better receive treatment and increases their confidence and hope in fighting cancer.

However, adagrasib still has some limitations, such as some patients may develop resistance to it and some patients may experience adverse reactions. Therefore, clinicians need to design individualized treatment plans based on the patient's specific conditions and closely monitor changes in the patient's condition.